Profile data is unavailable for this security.
About the company
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-52.20m
- Incorporated2003
- Employees42.00
- LocationCandel Therapeutics Inc117 Kendrick Street,, Suite 450NEEDHAM 02494United StatesUSA
- Phone+1 (617) 916-5445
- Fax+1 (302) 655-5049
- Websitehttps://www.candeltx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Repare Therapeutics Inc | 66.52m | -84.05m | 120.73m | 179.00 | -- | 0.6901 | -- | 1.81 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Lineage Cell Therapeutics Inc | 8.72m | -20.11m | 121.12m | 75.00 | -- | 1.83 | -- | 13.89 | -0.1096 | -0.1096 | 0.0474 | 0.3505 | 0.086 | -- | 20.83 | 116,253.30 | -19.77 | -19.53 | -22.80 | -22.59 | 95.00 | 89.13 | -229.91 | -370.88 | -- | -- | 0.0021 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Ventyx Biosciences Inc | 0.00 | -152.52m | 121.62m | 75.00 | -- | 0.436 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
Context Therapeutics Inc | 0.00 | -30.15m | 122.25m | 5.00 | -- | 1.46 | -- | -- | -0.9117 | -0.9117 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -55.16 | -- | -58.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Vigil Neuroscience Inc | 0.00 | -82.60m | 124.68m | 66.00 | -- | 1.37 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
Outlook Therapeutics Inc | 0.00 | -94.05m | 124.90m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
Coherus Biosciences Inc | 304.34m | -450.00k | 126.73m | 235.00 | -- | -- | 26.10 | 0.4164 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 127.29m | 36.00 | -- | -- | -- | 2.58 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Candel Therapeutics Inc | 0.00 | -52.20m | 127.70m | 42.00 | -- | -- | -- | -- | -1.74 | -1.74 | 0.00 | -0.4749 | 0.00 | -- | -- | 0.00 | -145.85 | -- | -227.04 | -- | -- | -- | -- | -- | -- | -30.42 | -- | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Adverum Biotechnologies Inc | 1.00m | -94.11m | 128.35m | 121.00 | -- | 0.8906 | -- | 128.35 | -6.03 | -6.03 | 0.0585 | 6.93 | 0.0046 | -- | -- | 8,264.46 | -43.66 | -36.39 | -50.24 | -39.04 | -- | -- | -9,411.10 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
Cardiff Oncology Inc | 689.00k | -43.01m | 129.37m | 31.00 | -- | 2.50 | -- | 187.76 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Skye Bioscience Inc | 0.00 | -21.24m | 129.85m | 11.00 | -- | 1.71 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Inhibikase Therapeutics Inc | 0.00 | -19.57m | 133.04m | 8.00 | -- | -- | -- | -- | -2.72 | -2.72 | 0.00 | -0.0711 | 0.00 | -- | -- | 0.00 | -175.81 | -66.49 | -267.87 | -85.55 | -- | -- | -- | -1,139.14 | -- | -- | -- | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 30 Sep 2024 | 1.03m | 3.21% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 897.18k | 2.80% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 492.01k | 1.53% |
Geode Capital Management LLCas of 30 Sep 2024 | 449.00k | 1.40% |
Banor Capital Ltd.as of 31 Mar 2024 | 398.83k | 1.24% |
Halter Ferguson Financial, Inc.as of 30 Sep 2024 | 304.54k | 0.95% |
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 158.77k | 0.50% |
Susquehanna Financial Group LLLPas of 30 Sep 2024 | 135.46k | 0.42% |
Bridgeway Capital Management LLCas of 30 Sep 2024 | 80.60k | 0.25% |
Teachers Advisors LLCas of 30 Sep 2024 | 66.22k | 0.21% |